InvestSMART

EMvision Medical Devices Limited (ASX: EMV) - Announcements

Current share price for EMV : $1.690 0.09 (5.62%)+

ASX company news and announcements for EMvision Medical Devices Limited (EMV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All EMvision Medical Devices Limited (EMV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than EMvision Medical Devices Limited (EMV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for EMvision Medical Devices Limited (EMV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$157 Firm Commitments for $12.0M Placement & Launch of SPP 17 Sep 2025 9:28AM $2.320 $1.690 fallen by 27.16%
$157 Date of AGM & Closing Date for Director Nominations 16 Sep 2025 8:47AM $2.320 $1.690 fallen by 27.16%
$157 Trading Halt 15 Sep 2025 9:40AM $2.320 $1.690 fallen by 27.16%
$157 EMVision Webinar & E&P Healthcare Conference Presentation 9 Sep 2025 8:47AM $1.980 $1.690 fallen by 14.65%
$157 EMVision Go-To-Market Strategy Webinar 5 Sep 2025 9:31AM $1.930 $1.690 fallen by 12.44%
$157 Appendix 4G & Corporate Governance Statement 28 Aug 2025 9:38AM $1.900 $1.690 fallen by 11.05%
$157 Appendix 4E & Annual Report to 30 June 2025 28 Aug 2025 9:37AM $1.900 $1.690 fallen by 11.05%
$157 UCLA Health Activation & Continuous Innovation Study Update 26 Aug 2025 9:14AM $1.810 $1.690 fallen by 6.63%
$157 EMVision Awarded $3m Grant For Regional Benefits Study 15 Aug 2025 9:09AM $1.705 $1.690 fallen by 0.88%
$157 Notification regarding unquoted securities - EMV 11 Aug 2025 3:39PM $1.750 $1.690 fallen by 3.43%
$157 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2025 8:17AM $1.765 $1.690 fallen by 4.25%
$157 First Responder Program Advanced & Grant Milestone Achieved 29 Jul 2025 8:40AM $1.795 $1.690 fallen by 5.85%
$157 Key Developments in Pivotal Trial & Innovation Study 2 Jul 2025 8:21AM $1.745 $1.690 fallen by 3.15%
$157 EMVision Awarded $5m Non-Dilutive Government Grant 16 Jun 2025 8:28AM $1.790 $1.690 fallen by 5.59%
$157 Non-Executive Director Appointment 5 Jun 2025 8:20AM $1.700 $1.690 fallen by 0.59%
$157 Initial Director's Interest Notice 5 Jun 2025 8:20AM $1.700 $1.690 fallen by 0.59%
$157 Additional Pivotal Trial Site Activations 3 Jun 2025 8:22AM $1.645 $1.690 risen by 2.74%
$157 Enhanced Algorithm Performance From Continuous Innovation 21 May 2025 8:42AM $1.695 $1.690 fallen by 0.29%
$157 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2025 8:08AM $1.990 $1.690 fallen by 15.08%
$157 Activation of Second US Pivotal Trial Site, Mayo Clinic 28 Apr 2025 8:25AM $1.950 $1.690 fallen by 13.33%
$157 Final Director's Interest Notice 16 Apr 2025 9:04AM $1.840 $1.690 fallen by 8.15%
$157 Non-Executive Director Retirement 16 Apr 2025 9:03AM $1.840 $1.690 fallen by 8.15%
$157 Emu Pivotal Validation Trial Commences 27 Mar 2025 8:15AM $1.975 $1.690 fallen by 14.43%
$157 Change of Share Registry Details 21 Mar 2025 5:16PM $1.990 $1.690 fallen by 15.08%
$157 First Responder Scanner in Successful Aeromedical Testing 19 Mar 2025 8:17AM $1.800 $1.690 fallen by 6.11%

51 - 75 of 371 results

Page 3 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.